ATP und Biolojic Design gründen Aulos Bioscience zur Entwicklung eines hochdifferenzierten IL-2-Antikörper-Ansatzes gegen Krebs finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
A Black man s risk of getting prostate cancer is 75% higher than it is for a White man and the disease is twice as deadly but genetic risks for people of various racial and ethnic groups is coming into focus.
ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer
Aulos Bioscience to Present at the 39th Annual J.P. Morgan Healthcare Conference
BOSTON and TEL AVIV, Israel, Jan. 8, 2021 /PRNewswire/ ATP, a leading life sciences venture capital firm, and Biolojic Design, a biotechnology company that computationally designs functional antibodies, today unveiled Aulos Bioscience, a new company that is developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors. ATP has committed $40 million in Series A funding to advance Aulos lead molecule from preclinical stage through clinical proof of concept, with human trials expected to start later this year.
About Sareum Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage. Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the cytokine storm immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802). Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad applicat
This article originally appeared on Undark.
When chatting at cocktail parties about his job, Mark Ratain, an oncologist and pharmacologist at the University of Chicago, often asks a short riddle: Your doctor gives you a prescription for a new drug. The pharmacist says, Make sure you take it on an empty stomach, twice a day. What do you think would happen if you took it with food?
Most don t get the answer right. Nobody would ever say, Well, I could die from an overdose, Ratain says.
Advertisement:
That s exactly what could happen to anyone taking the drug nilotinib approved by the U.S. Food and Drug Administration in 2007 to treat the blood cancer chronic myelogenous leukemia. The drug is among the most effective cancer therapies; a patient taking it may have a 96 percent chance of surviving the cancer for at least six years, according to one of the most recent long-term studies. But the FDA-approved label for nilotinib carries a black box warning: Take it on an empty s